Metoprolol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Metoprolol: Exploring a New Role in Malignant Renovascular Hypertension
One-Sentence Summary
Metoprolol is a β1-selective adrenergic blocker; no SAHPRA-approved original indication is on file for this candidate, and the drug is not currently marketed in South Africa. The TxGNN model predicts a possible role in Malignant Renovascular Hypertension, but this direction is currently supported by 0 clinical trials and only 2 tangentially related publications — this is an early-stage research hypothesis, not an evidence-backed indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no licensed indication text on file for this candidate |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| South Africa Market Status | Not Marketed (no SAHPRA-registered products) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is currently a data gap. Based on the pharmacology captured in the evidence pack, metoprolol is a β1-selective adrenergic blocker. β1 blockade at the juxtaglomerular apparatus is known to suppress renin secretion, which theoretically dampens the renin-angiotensin axis implicated in renovascular hypertension — giving the prediction a plausible mechanistic basis.
However, this rationale is inferential rather than evidence-based for this specific condition. No clinical trials and no directly relevant literature were found linking metoprolol to malignant renovascular hypertension. The two retrieved publications discuss related but distinct clinical scenarios (hypertensive optic neuropathy secondary to renal artery stenosis, and a diagnostic biomarker study for pheochromocytoma) rather than treatment outcomes for this indication. The mechanistic link should therefore be treated as a research hypothesis warranting further investigation, not as clinical evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15231398 | 2004 | Case report/Review | Survey of Ophthalmology | 26-year-old woman with hypertensive optic neuropathy (bilateral disk swelling, retinal exudates/infarcts) caused by renal artery stenosis secondary to Takayasu’s arteritis; does not evaluate metoprolol treatment. |
| 1988765 | 1991 | Diagnostic study (pheochromocytoma) | Medicine | Evaluates plasma chromogranin A as a diagnostic marker to differentiate pheochromocytoma from other causes of hypertension (83% sensitivity, 96% specificity); does not evaluate metoprolol treatment. |
Neither publication directly assesses metoprolol efficacy in malignant renovascular hypertension; both are included as background disease-context literature only.
South Africa Market Information
No SAHPRA registrations are on file for this candidate (0 licenses; market status: Not Marketed). No dosage form, product name, or approved indication text is currently available for South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: The mechanistic rationale (β1-blockade → renin suppression) is plausible, but evidence level is L4 with zero clinical trials and no literature directly evaluating this indication. The drug is also not currently registered or marketed in South Africa, and core safety data (PI warnings, contraindications) is missing — this is a Blocking gap that must be resolved before any safety evaluation can proceed.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI): warnings and contraindications (Blocking gap, DG001)
- Confirmed mechanism-of-action documentation from DrugBank (High-priority gap, DG002)
- Preclinical or mechanistic studies testing the renin-suppression hypothesis specifically in renovascular hypertension
- Clarification of South Africa market/registration pathway, since this candidate currently has zero SAHPRA licenses
- If pursuing further, note that other predicted indications for this drug (e.g., septal myocardial infarction, chronic pulmonary heart disease) currently carry stronger evidence levels (L3–L2) and may be more productive candidates to evaluate first
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.